Q1 Earnings Estimate for Metagenomi Issued By HC Wainwright

Metagenomi, Inc. (NASDAQ:MGX) – Investment analysts at HC Wainwright lifted their Q1 2025 EPS estimates for Metagenomi in a research note issued to investors on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.47) per share for the quarter, up from their previous estimate of ($0.56). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Metagenomi’s current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for Metagenomi’s Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.58) EPS and FY2025 earnings at ($2.10) EPS.

Separately, Wells Fargo & Company decreased their price objective on shares of Metagenomi from $25.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, March 18th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Metagenomi Trading Down 2.1 %

Metagenomi stock opened at $1.40 on Monday. Metagenomi has a 52 week low of $1.23 and a 52 week high of $10.50. The stock has a market cap of $52.34 million, a price-to-earnings ratio of -0.53 and a beta of -0.27. The company’s 50-day moving average price is $2.02 and its two-hundred day moving average price is $2.36.

Metagenomi (NASDAQ:MGX) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). The business had revenue of $9.61 million for the quarter, compared to analyst estimates of $13.18 million. Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. During the same period last year, the business posted ($20.05) earnings per share.

Hedge Funds Weigh In On Metagenomi

Several large investors have recently made changes to their positions in MGX. BNP Paribas Financial Markets raised its holdings in shares of Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after purchasing an additional 7,256 shares in the last quarter. Verition Fund Management LLC bought a new position in shares of Metagenomi in the third quarter valued at $82,000. Jacobs Levy Equity Management Inc. lifted its position in shares of Metagenomi by 209.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock valued at $296,000 after acquiring an additional 92,468 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Metagenomi by 105.8% during the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after acquiring an additional 173,796 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Metagenomi during the 3rd quarter worth $33,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.